Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

News from NKTR, BMY and MRK. See Also: Biotechs' Bizarre Performances in Early Trading Hours Today

News from Nektar Nektar Therapeutics ( NKTR ) announced that new data from patients with metastatic triple-negative breast cancer, who were enrolled in the PIVOT-02 study, will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference being held from September...

September 24, 2019

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals' Product CTX001™ for Severe SCD

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA CRISPR Therapeutics ( CRSP ) and Vertex Pharmaceuticals ( VRTX ) announced that the European Medicines Agency ( EMA ) granted Priority Medicines ( PRIME ) designation to...

September 22, 2020

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics ( NTLA ) is a genome editing company, focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both...

January 7, 2021

Underlining Exelixis Bright Future

Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results Exelixis ( EXEL ) announced its preliminary unaudited financial results for the Fourth Quarter and Full Year 2020. It also provided financial guidance for the full year...

January 11, 2021

The Medicines Company: Improving Atherosclerotic Cardiovascular Diseases (ASCVD)

The Medicines Company ORION-10 Study for ASCVD The Medicines Company ( MDCO ) announced positive topline results from the ORION-10 Phase 3 clinical trial in patients with atherosclerotic cardiovascular disease ( ASCVD ). The ORION-10 trial conducted with the product...

September 26, 2019

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA La Jolla Pharmaceutical Company ( LJPC ) announced today in a press release that it and certain of its wholly-owned subsidiaries, La Jolla collectively, have entered into...

January 12, 2021

Enanta Product EPD-305 Has Promising Results for the Treatment NASH

Enanta Positive Results of EPD-305 for NASH Enanta ( ENTA ) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305 for the treatment of non-alcoholic steatohepatitis ( NASH ). ...

September 28, 2019

Seattle Genetics' Product Tucatinib Beats Agressive Colorectal Cancer. The Stock Price Soars

Seattle Genetics Stock Rally Seattle Genetics ( SGEN ) stock has rallied today. It gained around $10; trading at over $85, nearing the Prohost 2019 $90 target. The reason for investors’ great enthusiasm is Seattle Genetics announcement of a presentation at the...

September 30, 2019

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

Sutro Biopharma Therapeutic Discovery and Technology Sutro Biopharma ( STRO ) uses precise protein engineering and rational design for therapeutic discovery. The firm’s proprietary integrated cell-free protein synthesis platform known as XpressCF® and site-specific conjugation platform XpressCF+™ led to the...

January 21, 2021

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1 From London we learned that ViiV Healthcare announced that the US Food and Drug Administration ( FDA ) approved Cabenuva, the first and only complete long-acting regimen for the...

January 25, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024